Document is current
Any future updates will be listed below
-
Authors
Sorg, Anna-Lisa https://orcid.org/0000-0002-6255-7758
Bergfeld, Leon
Jank, Marietta
Corman, Victor https://orcid.org/0000-0002-3605-0136
Semmler, Ilia
Goertz, Anna
Beyerlein, Andreas https://orcid.org/0000-0001-6603-5036
Verjans, Eva
Wagner, Norbert
Von Bernuth, Horst https://orcid.org/0000-0002-5812-7675
Lander, Fabian
Weil, Katharina
Hufnagel, Markus
Spiekerkoetter, Ute https://orcid.org/0000-0002-5385-6705
Chao, Cho-Ming
Naehrlich, Lutz
Muntau, Ania Carolina
Schulze-Sturm, Ulf https://orcid.org/0000-0001-9539-5356
Hansen, Gesine
Wetzke, Martin
Jung, Anna-Maria
Niehues, Tim
Fricke-Otto, Susanne
Von Both, Ulrich https://orcid.org/0000-0001-8411-1071
Huebner, Johannes https://orcid.org/0000-0003-1232-4646
Behrends, Uta
Liese, Johannes G.
Schwerk, Christian https://orcid.org/0000-0002-1706-0259
Drosten, Christian https://orcid.org/0000-0001-7923-0519
Von Kries, Ruediger https://orcid.org/0000-0003-3646-0714
Schroten, Horst
- License Information
-
More Information
Article History
Received: 10 December 2021
Accepted: 28 April 2022
First Online: 6 June 2022
Competing interests
: The study centres received academic research funding from the Federal Ministry of Education and Research (BMBF) for study planning, study management and reimbursement for the assay of this study. V.C. reported a patent on methods and reagents for diagnosis of SARS-CoV-2 infection (Pub number 20210190797) of Charité and Euroimmun GmbH.H.v.B. reported receiving honoraria for ongoing reports on the safety profile of an IgG-product from Octapharma GmBH, honoraria for lectures from CSL Behring, honoraria for advisory boards from Takeda and Swedish Orphan Biovitrum AB (publ) (SobiTM) and the ‘treatment guideline for Primary ‘immunodeficiencies’ is under his unpaid leadership. L.N. reported institutional fees for study participation by the German Centre for Lung Research, Vertex Pharmaceuticals and Boehringer Ingelheim. He participates on Trial Steering Committee for CF STORM and is the medical leader of the German CF-registry, and the pharmacovigilance study manager of the ECFSPR.G.H. reported receiving consulting fees from Sanofi GmbH and honoraria for lectures from MedUpdate and Abbvie.No other disclosures were reported.
